GlassScriptPhysician profile
William N Mitchell
NPI 1720037401
$7,837.60
in general payments reported to CMS, 2019-2025
25 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $218 · 2021: $513 · 2022: $1,264 · 2023: $2,465 · 2024: $942 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,641 · Long Term Medical Supply Or Device Loan: $1,331 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,641.32 |
| Long Term Medical Supply Or Device Loan | $1,331.45 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,470.50 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Carl Zeiss Meditec USA, INC. | $1,331.45 | 2023 | Artevo 800 |
| Glaukos Corporation | $453.65 | 2022-2025 | Idosetr, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Photrexa Cross-Linking Kit |
| Abbvie INC. | $394.97 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $378.92 | 2019-2023 | Tecnis Iol |
| Ivantis, INC | $268.02 | 2019-2021 | |
| Allergan, INC. | $201.93 | 2020-2022 | |
| New World Medical,INC. | $200.34 | 2020-2025 | Streamline, Ahmed Glaucoma Valve, Clearpath |
| Sun Pharmaceutical Industries INC. | $166.70 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $141.87 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $131.05 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $118.33 | 2023-2024 | Ultomiris |
| Bausch & Lomb Americas INC. | $98.54 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Rxsight INC | $94.15 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Mallinckrodt Hospital Products INC. | $74.89 | 2024-2025 | Acthar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $62.11 | 2024 | Omni Surgical System |
| Oyster Point Pharma, INC. | $54.35 | 2022-2023 | Tyrvaya |
| Ocular Therapeutix, INC. | $43.62 | 2022-2024 | Dextenza |
| Thea Pharma INC. | $38.68 | 2024 | Iyuzeh |
| Pfizer INC. | $25.52 | 2025 | |
| Array Biopharma INC | $22.97 | 2020 | |
| Eyepoint US, INC. | $17.41 | 2019 | |
| Eyevance Pharmaceuticals LLC | $17.10 | 2019 | |
| Iridex Corporation | $16.94 | 2019 | |
| Horizon Therapeutics Plc | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.